Table 2:

Mean clinical severity score and duration of neurobehavioral signs slopes by treatment group^a

	Clinical severity scores (points/d)			Duration neurobehavioral signs (min/d)
	Slope both sexes	Slope males	Slope females	Slope both sexes	Slope males	Slope females
Imidacloprid dose
0.00 mg/kg/d	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
0.03 mg/kg/d	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
0.34 mg/kg/d	−0.01 ± 0.02	−0.01 ± 0.03	0.00 ± 0.00	−0.27 ± 1.20	−0.54 ± 1.69	0.00 ± 0.00
3.42 mg/kg/d	−0.07 ± 0.15	−0.04 ± 0.11	−0.10 ± 0.18	−0.42 ± 4.69	−0.30 ± 5.05	−0.54 ± 4.57
10.25 mg/kg/d	−0.01 ± 0.08	−0.01 ± 0.07	−0.01 ± 0.09	1.46 ± 12.67	−1.11 ± 12.90	4.03 ± 12.54
15.50 mg/kg/d	−0.10 ± 0.10*^	−0.05 ± 0.08	−0.15 ± 0.10^	−6.55 ± 9.51*	−2.33 ± 10.09	−10.76 ± 7.05*~

^aA linear regression line was fitted for the clinical severity scores and the change in duration of neurobehavioral signs in each individual domestic chicken after oral imidacloprid exposure over the 7 day exposure period. The slope of the liner regression line was a representation of how an individual changed over time. The individual bird slope values were used to calculate a treatment group mean slope ± standard deviation of the clinical severity scores and duration of neurobehavioral signs. The treatment group mean slope is presented in this table. A Wilcoxon signed-rank test was performed within each treatment group to test if the slope values were significantly different from zero. A Kruskal-Wallis test was performed to compare the mean slope between treatment groups.

^*Slope was significantly different from zero p ≤ 0.01

^{^}Slope is significantly different than the 10.25 mg/kg/d group p ≤ 0.04

^~Slope is significantly different than the 3.42 and 10.25 mg/kg/d groups p ≤ 0.018